Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral and laboratory data that will support the next study that will inquire whether young plasma infusions improve or slow the progression of cognitive, mood and/or motor impairment and rate markers of the disease.


Clinical Trial Description

Parkinson's disease (PD) is a neurodegenerative disease that affects over 1.6 million people in the United States and whose incidence increases with age, affecting over 1% of people over the age of 65. The neuropathological processes involved in PD are widespread throughout the brain, and are reflected in a constellation of motor, cognitive, mood and other non-motor symptoms. Treatments to date have largely focused on dopamine replacement strategies or deep brain stimulation, both symptomatic treatments. As neurodegenerative diseases progress, there are major changes throughout the body and brain. These changes are transmitted in the body via the circulatory system between organs, tissues and cells. Recent findings from multiple laboratories have shown that infusions of young plasma into aging rodents can have beneficial effects on cognitive functions. This suggests that the circulating components of plasma can improve cognitive and disease-relevant symptoms. This has motivated the field to treat multiple disorders with blood products and their constituent active components. The established safety of blood transfusions allows the investigators to test whether infusions of young plasma can ease the neurological symptoms in human subjects with neurodegenerative diseases. A related study of plasma infusions has already been completed at Stanford in patients with Alzheimer's disease (ClinicalTrials.gov identifier NCT02256306). The investigator proposes to test the safety and efficacy of transfusing young plasma into PD participants, in order to establish its effects on motor and cognitive functions in participants in a Phase 1 study. The successful completion of this study will inform the design of future, larger and multicenter studies with the goal to determine whether infusions of young plasma can ameliorate the neurodegenerative symptoms and underlying pathophysiology in Parkinson's disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02968433
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 1
Start date November 2016
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT06245174 - A Smartphone Application for Neurology and Telemedicine
Completed NCT02656355 - Gait Initiation Difficulty and Anticipatory Postural Adjustment (APA) Impairment in People With PD - Evaluation and Training N/A
Completed NCT04193527 - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Phase 3
Completed NCT04748263 - Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)
Recruiting NCT06367101 - AR Stimulation Effects on Gait, Anxiety, and Brain Connectivity in Parkinson's Disease N/A
Completed NCT06355947 - Cycling and Treadmill With Dual Task for Parkinson's Disease Improvement N/A
Completed NCT01971528 - Central and Peripheral Fatigue in Individuals With Parkinson's Disease - Evaluation and Training N/A
Completed NCT05113524 - Effects of Dance on the Turning Characteristics of Patients With Parkinson's Disease N/A